With 2026 set to be a banner year for M&A as buyers facing patent cliffs compete for a limited pool of late-stage assets [3], companies demonstrating disciplined pivotal execution and FDA alignment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results